At the conclusion of this session, participants will be able to:
- critically appraise the literature supporting temporary MCS use in cardiogenic shock;
- integrate the rational use of PACs into clinical practice of hemodynamically unstable patients with cardiogenic shock;
- appraise the strengths and weaknesses randomized controlled trials of first line vasoactive therapies in patients with shock; and
- provide an overview of the effect of positive end expiratory pressure has on cardiovascular hemodynamics.
Many aspects of cardiogenic shock care are assumed or proposed to be beneficial, but the evidence underpinning these management strategies may be lacking. The symposia plans to highlight the guideline and/or expert rationale for routine care options listed in the run of the show. At the end of each 7 min presentation another Canadian expert will be allowed to make a brief 3 minute counterpoint and convey to the audience the poor evidence underpinning the management strategy and/or common scenarios where it may not apply.